Efficacy and safety of early pancreatic duct stenting for unresectable pancreatic cancer: A randomized controlled trial

Table 5 Comparison of analgesic drug use between the two groups, n (%)

		None	Nonopioid analgesic	Moderate opioid	Strong opioid	P value
After 1 month	Double-stent group	24 (60.0)	13 (32.5)	1 (2.5)	2 (5.0)	0.026
	Single-stent group	11 (28.9)	19 (42.1)	5 (13.2)	3 (7.9)
After 2 months	Double-stent group	22 (55.0)	14 (35.0)	2 (5.0)	2 (5.0)	0.051
	Single-stent group	10 (26.3)	18 (47.4)	4 (10.5)	6 (15.8)
After 3 months	Double-stent group	19 (57.5)	18 (57.5)	1 (2.5)	2 (5.0)	< 0.001
	Single-stent group	6 (15.8)	14 (36.8)	8 (21.1	10 (36.3)
After 6 months	Double-stent group	16 (40.0)	16 (40.0)	5 (12.5)	3 (7.5)	< 0.001
	Single-stent group	3 (7.9)	3 (7.9)	16 (42.1)	16 (42.1)

The double-stent group underwent endoscopic retrograde cholangiopancreatography with a fully-covered self-expandable metallic biliary stent and a pancreatic duct stent, while the single-stent group underwent a fully-covered self-expandable metallic biliary stent only.